文献速递肺结节与肺癌

肿瘤来源自身抗体可识别恶性肺结节

Tumor-derived Autoantibodies Identify Malignant Pulmonary Nodules.
PubMed 文献 · Am J Respir Crit Care Med · 2019-01-01

研究通过高密度蛋白芯片从10例切除的肺部肿瘤B细胞中分离自身抗体,并在250例结节阳性患者中验证。13种自身抗体对肺癌灵敏度≥50%、特异度≥70%,其中4种联合检测恶性结节的AUC为0.74,在8-20mm不确定结节亚组中AUC为0.78。提示肿瘤来源自身抗体可作为恶性肺结节的血液生物标志物。

要点

  • 肿瘤B细胞来源的13种自身抗体对肺癌灵敏度≥50%、特异度≥70%。
  • 4种自身抗体联合检测恶性结节AUC为0.74,8-20mm结节亚组AUC为0.78。
  • 该方法有望为低剂量CT筛查中的结节良恶性判断提供无创血液检测手段。

核心结论

  • 肿瘤来源自身抗体可有效作为恶性肺结节诊断的血液生物标志物。

研究设计与样本

  • 从10例切除的肺部肿瘤B细胞中分离自身抗体,用高密度蛋白芯片定义特异性。
  • 在相同10例患者及匹配的良性结节对照血浆中检测自身抗体(游离或与抗原复合)。
  • 在独立250例结节阳性患者队列中进一步验证有前景的自身抗体。

主要发现

  • 13种肿瘤B细胞来源自身抗体对肺癌灵敏度≥50%、特异度≥70%。
  • 血浆中13种自身抗体有11种同时以抗原复合和游离形式存在。
  • 在250例验证队列中,13种自身抗体有5种在癌症中仍显著升高。
  • 4种自身抗体联合检测恶性结节的AUC为0.74,在8-20mm不确定结节亚组AUC为0.78。

临床怎么用

  • 对于CT检出的肺结节,可考虑检测肿瘤来源自身抗体组合辅助判断良恶性。
  • 尤其适用于8-20mm的不确定结节,以减少不必要的侵入性随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Screening for non-small cell lung cancer is associated with earlier diagnosis and reduced mortality but also increased harm caused by invasive follow-up of benign pulmonary nodules. Lung tumorigenesis activates the immune system, components of which could serve as tumor-specific biomarkers. Objectives: To profile tumor-derived autoantibodies as peripheral biomarkers of malignant pulmonary nodules. Methods: High-density protein arrays were used to define the specificity of autoantibodies isolated from B cells of 10 resected lung tumors. These tumor-derived autoantibodies were also examined as free or complexed to antigen in the plasma of the same 10 patients and matched benign nodule control subjects. Promising autoantibodies were further analyzed in an independent cohort of 250 nodule-positive patients. Measurements and Main Results: Thirteen tumor B-cell-derived autoantibodies isolated ex vivo showed greater than or equal to 50% sensitivity and greater than or equal to 70% specificity for lung cancer. In plasma, 11 of 13 autoantibodies were present both complexed to and free from antigen. In the larger validation cohort, 5 of 13 tumor-derived autoantibodies remained significantly elevated in cancers. A combination of four of these autoantibodies could detect malignant nodules with an area under the curve of 0.74 and had an area under the curve of 0.78 in a subcohort of indeterminate (8-20 mm in the longest diameter) pulmonary nodules. Conclusions: Our novel pipeline identifies tumor-derived autoantibodies that could effectively serve as blood biomarkers for malignant pulmonary nodule diagnosis. This approach has future implications for both a cost-effective and noninvasive approach to determine nodule malignancy for widespread low-dose computed tomography screening.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Lastwika KJ, Kargl J, Zhang Y, et al. Tumor-derived Autoantibodies Identify Malignant Pulmonary Nodules. Am J Respir Crit Care Med. 2019. PMID: 30422669. doi:10.1164/rccm.201804-0628OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。